# An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

> **NCT03154437** · — · APPROVED_FOR_MARKETING · sponsor: **Genentech, Inc.**

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Emicizumab

## Key facts

- **NCT ID:** NCT03154437
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03154437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03154437, "An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03154437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*